|
|
Cell Signalling Pathways:Productive Sources of Pharmaceutical TargetsPublished by: Drug and Market Development Publishing Published: Jun. 1, 2004 - 210 Pages Table of ContentsChapter 1: Executive Summary Chapter 2: Introduction Membrane Receptor Pathways Mitogen-Activated Protein Kinase Pathways Extracellular Signal-Related Kinase (ERK) Pathway Stress Activated Protein Kinase (SAPK) Pathway P38 MAPK Pathway G-Protein Coupled Receptors PI3K/Akt Signalling Jak/STAT Signalling NF-êB Signalling Insulin Signalling B Cells and T Cells Nuclear Receptors Nuclear Receptor Structure Nuclear Receptors as Pharmaceutical Targets Chapter 3: Cancer Market for Novel Therapies Cell Cycle Control Manipulation of the Cell Cycle to Enhance the Therapeutic Window Mechanism-Based Protection of Normal Cells p53-Dependent Checkpoints Growth Factor Activated Pathways CDK Inhibitors Cyclin-Dependent Kinase Modulators in Clinical Development Flavopiridol Trastuzumab and Flavopiridol Epothilone B and Flavopiridol Imatinib and Flavopiridol UCN-01 Molecular Targets for Cancer Drug Development Bcl-2 Bcr/Abl Cyclo-oxygenase The ErbB Family ErbB2 Epidermal Growth Factor Receptor Farnesyl Transferase FLT3 Heat Shock Protein 90 Kit Mammalian Target of Rapamycin (mTOR) Mitogen Activated ERK Kinase (MEK) Proteasome Protein Kinase C Raf-1 Kinase Src Protein Kinase Vascular Endothelial Growth Factor Signal Transduction Modulators in Clinical Development for Cancer Critical Aspects of Clinical Trial Design 17-AAG Affinitak™ AP23573 AP23464 ARRY-142886 AZD3409 BAY 43-9006 Bevacizumab (Avastin™) Bortezomib (Velcade™) CCI-779 Celecoxib (Celebrex®) CEP-701 CEP-7055 CI-1033 CI-1040 EKB-569 EMD72000 Erlotinib HCl Gefitinib GW572016 Imatinib Mesylate Lonafarnib (Sarasar™) MLN518 Oblimersen (Genasense™) OSI-461 Pertuzumab(Omnitarg™) PKC-412 RAD001 SU11248 Tipifarnib (Zarnestra®) Trastuzumab (Herceptin®) Vatalanib (PTK787) VEGF Trap ZD6474 Nuclear Receptors Targets for Cancer Therapy Androgen Receptor Estrogen Receptor (ER) Progesterone Receptor (PR) Nuclear Receptor Modulators as Cancer Therapeutics Selective Estrogen Receptor Modulators (SERMS) Aromatase Inhibitors Fulvestrant (Faslodex®) Signal Transduction Inhibitors and Endocrine Therapy Prostate Cancer: Targeting the Androgen Receptor Flavonoids and AR Activity Proteasome Activity and AR Function Nuclear Receptors as Targets for Chemoprevention Vitamin D Receptor (VDR) Retinoic Acid Receptors (RAR and RXR) Retinoids in Chemoprevention Chapter 4: Inflammatory/Autoimmune Disease Molecular Targets for Anti-Inflammatory Drugs Chemokines Cyclooxygenase Glucagon-like Peptide 2 Glucocorticoid Receptor (GR) Glucocorticoid Receptor and Rheumatoid Arthritis Intercellular Adhesion Molecule 1 Interleukin-1 Retinoid-Related Orphan Receptor á (RORá) and Inflammation Tumor Necrosis Factor Rheumatoid Arthritis Signal Transduction Modulators in Development for Rheumatoid Arthritis Adalimumab (Humira®) Anakinra (Kineret®) Belimumab (LymphoStat-B™) CTLA4Ig (Abatacept) Etanercept (Enbrel®) IL-1 Trap Infliximab (Remicade®) ISIS 104838 MLN1202 PRO70769 Rituximab (Rituxan®) Inflammatory Bowel Disease Signal Transduction Modulators in Clinical Development for Inflammatory Bowel Diseases ALX-0600 (Teduglutide) Alicaforsen (ISIS2302) Adalimumab (Humira®) CDP-870 CNI-1493 (Semapimod) Traficet-EN™ Multiple Sclerosis Targeted Drug Candidates in Development for MS MBP8298 NBI-5788 Chapter 5: Metabolic Syndrome Molecular Targets for Drugs to Treat Metabolic Syndrome â3-Adrenoceptor Glucagon-Like Peptide 1 Leptin Peroxisome Proliferator Activated Receptor (PPAR) PPARä Protein Kinase C-â Protein Tyrosine-Phosphatase 1B Diabetes (Type 2) Anti-Diabetic Drugs in Clinical Development Balaglitazone CJC-1131 (DAC-GLP-1) Exenatide (exendin-4) ISIS 113715 LAF 237 Liraglutide (NN2211) LY333531 (Ruboxistaurin) LY818 LY929 MBX-102 Muraglitazar Pioglitazone (Actos®) Rosiglitazone (Avandia®) T131 Tesaglitazar (Galida™) Obesity Anti-Obesity Drugs in Clinical Development Acomplia™ (rimonabant) AOD9604 Axokine® PYY 3-36 Nasal Formulation T71 Chapter 6: Company Profiles Abbott Laboratories Amylin Pharmaceuticals Ariad Pharmaceuticals Array BioPharma AstraZeneca Aventis Bayer BioMS Medical Bristol-Myers Squibb CellTech Cephalon ChemoCentryx ConjuChem Eli Lilly EMD Pharmaceuticals Genentech Genta GlaxoSmithKline Human Genome Sciences Ilex Oncology Isis Pharmaceuticals Johnson and Johnson Ligand Pharmaceuticals Metabolex Metabolic Pharmaceuticals Millennium Nastech Pharmaceutical Company Neurocrine Biosciences Novartis Novo Nordisk NPS Pharmaceuticals Onyx OSI Pharmaceuticals Pfizer Regeneron Sanofi-Synthelabo Schering Plough Tularik Wyeth Chapter 7: Concluding Remarks Promising Cancer Drug Candidates Promising Drug Candidates for Inflammatory and Autoimmune Diseases Promising Drug Candidates for Metabolic Syndrome AbstractSignal transduction, or cell signalling, is the mechanism by which multi-cellular organisms organize activities and maintain homeostasis. The coordination of multiple events enables cells to grow and function properly in a healthy organism, and the loss of control at any stage usually results in disease. This report will provide an overview of what is currently known about critical signalling pathways, highlighting the proteins and interactions that go awry in disease, and exploring the potential for the exploitation of these key proteins as targets for pharmaceutical drug development.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||